BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 17342327)

  • 1. PTEN and phosphorylated AKT expression and prognosis in early- and late-stage non-small cell lung cancer.
    Lim WT; Zhang WH; Miller CR; Watters JW; Gao F; Viswanathan A; Govindan R; McLeod HL
    Oncol Rep; 2007 Apr; 17(4):853-7. PubMed ID: 17342327
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Expression of phosphorylated protein kinase B and PTEN protein in ovarian epithelial cancer].
    Qiao YH; Cheng J; Guo RX
    Zhonghua Fu Chan Ke Za Zhi; 2007 May; 42(5):325-9. PubMed ID: 17673045
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Expression and significance of PTEN/PI3K signal transduction-related proteins in non-small cell lung cancer].
    Liao DW; Wang L; Zhang XG; Liu MQ
    Ai Zheng; 2006 Oct; 25(10):1238-42. PubMed ID: 17059767
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phosphorylated Akt overexpression and loss of PTEN expression in non-small cell lung cancer confers poor prognosis.
    Tang JM; He QY; Guo RX; Chang XJ
    Lung Cancer; 2006 Feb; 51(2):181-91. PubMed ID: 16324768
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical significance of insulin receptor substrate-I down-regulation in non-small cell lung cancer.
    Han CH; Cho JY; Moon JT; Kim HJ; Kim SK; Shin DH; Chang J; Ahn CM; Kim SK; Chang YS
    Oncol Rep; 2006 Dec; 16(6):1205-10. PubMed ID: 17089038
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Loss of PTEN expression is not uncommon, but lacks prognostic value in stage I NSCLC.
    Olaussen KA; Soria JC; Morat L; Martin A; Sabatier L; Morere JF; Khayat D; Spano JP
    Anticancer Res; 2003; 23(6C):4885-90. PubMed ID: 14981940
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Centromere protein H is a novel prognostic marker for human nonsmall cell lung cancer progression and overall patient survival.
    Liao WT; Wang X; Xu LH; Kong QL; Yu CP; Li MZ; Shi L; Zeng MS; Song LB
    Cancer; 2009 Apr; 115(7):1507-17. PubMed ID: 19170237
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunohistochemical characterization of the mTOR pathway in stage-I non-small-cell lung carcinoma.
    Shin E; Choi CM; Kim HR; Jang SJ; Park YS
    Lung Cancer; 2015 Jul; 89(1):13-8. PubMed ID: 25936472
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Frequent activation of AKT in non-small cell lung carcinomas and preneoplastic bronchial lesions.
    Balsara BR; Pei J; Mitsuuchi Y; Page R; Klein-Szanto A; Wang H; Unger M; Testa JR
    Carcinogenesis; 2004 Nov; 25(11):2053-9. PubMed ID: 15240509
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor expression of S100A6 correlates with survival of patients with stage I non-small-cell lung cancer.
    De Petris L; Orre LM; Kanter L; Pernemalm M; Koyi H; Lewensohn R; Lehtiö J
    Lung Cancer; 2009 Mar; 63(3):410-7. PubMed ID: 18620780
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phosphorylated Akt expression is a prognostic marker in early-stage non-small cell lung cancer.
    Yip PY; Cooper WA; Kohonen-Corish MR; Lin BP; McCaughan BC; Boyer MJ; Kench JG; Horvath LG
    J Clin Pathol; 2014 Apr; 67(4):333-40. PubMed ID: 24265323
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunohistochemical detection of phosphorylated Akt, PI3K, and PTEN in ameloblastic tumors.
    Kumamoto H; Ooya K
    Oral Dis; 2007 Sep; 13(5):461-7. PubMed ID: 17714348
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of PTEN and FHIT is involved in regulating the balance between apoptosis and proliferation in lung carcinomas.
    Zheng H; Tsuneyama K; Takahashi H; Miwa S; Nomoto K; Saito H; Masuda S; Takano Y
    Anticancer Res; 2007; 27(1B):575-81. PubMed ID: 17348444
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinicopathologic and molecular significance of phospho-Akt expression in early invasive breast cancer.
    Aleskandarany MA; Rakha EA; Ahmed MA; Powe DG; Ellis IO; Green AR
    Breast Cancer Res Treat; 2011 Jun; 127(2):407-16. PubMed ID: 20617378
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phospho-Akt overexpression in non-small cell lung cancer confers significant stage-independent survival disadvantage.
    David O; Jett J; LeBeau H; Dy G; Hughes J; Friedman M; Brody AR
    Clin Cancer Res; 2004 Oct; 10(20):6865-71. PubMed ID: 15501963
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Erythropoietin and erythropoietin receptor coexpression is associated with poor survival in stage I non-small cell lung cancer.
    Saintigny P; Besse B; Callard P; Vergnaud AC; Czernichow S; Colombat M; Girard P; Validire P; Breau JL; Bernaudin JF; Soria JC
    Clin Cancer Res; 2007 Aug; 13(16):4825-31. PubMed ID: 17699861
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vascular endothelial growth factor immunostaining correlates with postoperative relapse and survival in non-small cell lung cancer.
    Yilmaz A; Ernam D; Unsal E; Demirag F; Atikcan S; Taştepe I
    Arch Med Res; 2007 Oct; 38(7):764-8. PubMed ID: 17845896
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activated Akt signaling pathway in invasive ductal carcinoma of the breast: correlation with HER2 overexpression.
    Park SS; Kim SW
    Oncol Rep; 2007 Jul; 18(1):139-43. PubMed ID: 17549359
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictive value of MMP-7 expression for response to chemotherapy and survival in patients with non-small cell lung cancer.
    Liu H; Zhang T; Li X; Huang J; Wu B; Huang X; Zhou Y; Zhu J; Hou J
    Cancer Sci; 2008 Nov; 99(11):2185-92. PubMed ID: 18823373
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical significance of aminopeptidase N in non-small cell lung cancer.
    Tokuhara T; Hattori N; Ishida H; Hirai T; Higashiyama M; Kodama K; Miyake M
    Clin Cancer Res; 2006 Jul; 12(13):3971-8. PubMed ID: 16818694
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.